Time to rethink the unthinkable: Upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
M. Kieran
DOI: https://doi.org/10.1002/pbc.25266
2015-01-01
Pediatric Blood & Cancer
Abstract:O ver the last 50 years, the dogma related to the biopsy of patients with diffuse intrinsic pontine gliomas (DIPG) has been clear. Due to excessive surgical toxicity and the ability to diagnose patients based on clinical symptoms (less than 3 months duration with cranial nerve deficits and long track signs) and classic radiographic findings (diffuse expansion of greater than 50% of the pons, dark on T1, bright on T2 and little or no enhancement) [1], biopsy has been considered not just unnecessary, but actually contraindicated [2]. This approach was supported by all of the available data at the time it was proposed and is quoted in almost all textbooks as fact. Times are changing: dramatic improvements in neuroimaging and stereotactic techniques, coupled with significant advances in molecular biology, wherewe can now sequence the entire genome of individual cells, has resulted in two major changes. First, in highly controlled circumstances and with appropriate expertise, safely biopsying the pons of patients with this terrible disease is possible [3], which means obtaining tumor material that can give clues to the underlying biology of this cancer. Several papers reporting on the identification of a number of new, previously unknownmutations in these tumors, and their differences from other non-pontine malignant gliomas, opens the door to novel avenues of therapeutic intervention [4–7]. Second, pediatric oncology is moving away from clinical trials based on minor iterations of the same group of similar, conventional chemotherapeutic agents, to the incorporation of newly developed biologic targeted drugs. In order to benefit from the molecular revolution and these new inhibitors (small molecule, immunotherapy, anti-angiogenic, epigenetic, etc), biopsy of tumors will be needed, particularly if we want to provide the appropriate personalized therapy for what we now recognize to be a very heterogeneous disease [8]. The question becomes: How do we change dogma in a safe and orderly manner? Just because some highly specialized centers can safely perform a biopsy of the pons must not be seen as an open invitation for every neuro–oncology program to consider it the standard of care. The FDA has determined that given the significant and potentially fatal risks of pontine biopsy in pediatric patients, the utilization of this technique for purely research indications is not justified. In this edition of PBC,Wang et al. [9] report on their single institutional experience with the up-front stereotactic biopsy of fifteen DIPG patients. While no surgical mortality or permanent deficits were observed, 20% of patient experienced transient or worsening deficits, something that must be considered in a patient population with a median survival of only nine months. The stated aim of up-front biopsy in this manuscript was to exclude tumors of the pons that mimicked DIPG based on overlapping clinical and radiographic appearance. The authors noted that one of the first cases biopsied at their institution turned out to be a brainstemPNET, which changed the upfront therapy and potentially the outcome for this patient. Most other reported cases have also been performed on classical DIPG lesions to exclude diseases other than DIPG (like PNET), or for atypical lesions that do not meet the clinical or radiographic criteria of DIPG and thus might also be something other than DIPG. Clearly, each center will make their own determination of what is appropriate clinical care and the risk/ benefit ratio of this procedure. The first major report of upfront stereotactic biopsy of DIPG patients was reported in 2007 by Roujeau et al. [3], where 24 patients underwent stereotactic biopsy, two (8%) of whom suffered transient deficits. Like the patient population being reported in this issue, this landmark French series performed biopsies with the goal of confirming both the grade and histology of the tumor on the premise that clinical criteria and MRI imaging alone were insufficient to predict outcome in all patients. Many DIPG clinical trials with a variety of treatment regimens have identified a very small group of long term survivors in spite of the characteristic clinical presentation andMRI appearance, suggesting that some presumed DIPG patients are either a different histology (as argued above), or a rare, curable subset of pontine glioma [10]. At the Dana-Farber Cancer Institute and Boston Children’s Hospital, we have taken a different approach. After 50 years of making no progress in the outcome of DIPG, we recognized that the expertise existed to obtain tumor tissue of classically presenting cases for which molecular analyses could be used to determine treatment. The first prospective national multi-institutional clinical trial of up-front stereotactic biopsy of classic DIPG (NCT01182350) used to stratify patients to different therapies based on the MGMT (temozolomide) and EGFR (erlotinib) expression of the tumor in combination with focal radiation therapy and bevacizumab, is underway. In order to partake in this clinical trial, all sites had to agree to significant regulatory oversight in order tomaximize patient safety, and all neurosurgeons were required to undergo a training